Contact
searchSearch
HMP Global
Login
Claire Harrison, MD
Videos
Selinexor Plus Ruxolitinib as a Frontline Combination in Patients With Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Claire Harrison, MD
Videos
First-in-Class Mutant CALR Antibody Demonstrates Durable Clinical Activity in Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Prithviraj Bose, MD
Videos
Earlier Momelotinib Treatment May Improve Outcomes in Myelofibrosis
06/23/2026
Prithviraj Bose, MD
Prithviraj Bose, MD, discusses post hoc analyses from the SIMPLIFY-1 and MOMENTUM trials showing that momelotinib provides meaningful spleen, symptom, and anemia benefits across myelofibrosis risk groups, with several outcomes appearing more...
Prithviraj Bose, MD, discusses post hoc analyses from the SIMPLIFY-1 and MOMENTUM trials showing that momelotinib provides meaningful spleen, symptom, and anemia benefits across myelofibrosis risk groups, with several outcomes appearing more...
Prithviraj Bose, MD, discusses...
06/23/2026
Oncology
Binod Dhakal, MD
Videos
Allogeneic BCMA CAR T-Cell Therapy Demonstrates Durable Activity and Manageable Safety in Relapsed or Refractory Multiple Myeloma
06/23/2026
Binod Dhakal, MD
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses...
06/23/2026
Oncology
Saurabh Chhabra, MD
Videos
Etentamig Demonstrates Durable Activity Following Prior BCMA Therapy in Multiple Myeloma
06/23/2026
Saurabh Chhabra, MD
Saurabh Chhabra, MD, discusses results from the phase 1b MOVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses results from the phase 1b MOVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses...
06/23/2026
Oncology
Benoit Tessoulin, MD, PhD
Videos
Epcoritamab Improves Outcomes Regardless of Risk Profile in Relapsed Follicular Lymphoma
06/23/2026
Benoit Tessoulin, MD, PhD
Benoit Tessoulin, MD, PhD, discusses subgroup analyses from the phase 3 EPCORE FL-1 trial showing that epcoritamab plus lenalidomide and rituximab provided consistent progression-free survival benefits across all major risk groups in patients...
Benoit Tessoulin, MD, PhD, discusses subgroup analyses from the phase 3 EPCORE FL-1 trial showing that epcoritamab plus lenalidomide and rituximab provided consistent progression-free survival benefits across all major risk groups in patients...
Benoit Tessoulin, MD, PhD,...
06/23/2026
Oncology
Roberto Mina, MD
Videos
MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma
06/23/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses...
06/23/2026
Oncology
Christopher Fox, MD, PhD
Videos
Epcoritamab Produces Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
06/23/2026
Christopher Fox, MD, PhD
Christopher Fox, MD, PhD, discusses results from the phase 3 EPCORE DLBCL-1 trial showing that epcoritamab significantly improved progression-free survival, complete response rates, duration of response, and time to next treatment compared...
Christopher Fox, MD, PhD, discusses results from the phase 3 EPCORE DLBCL-1 trial showing that epcoritamab significantly improved progression-free survival, complete response rates, duration of response, and time to next treatment compared...
Christopher Fox, MD, PhD,...
06/23/2026
Oncology
Georg Lenz, MD
Videos
Tafasitamab Plus Lenalidomide-R-CHOP as a New Option for High-Risk Aggressive B-Cell Lymphomas
06/18/2026
Georg Lenz, MD
Georg Lenz, MD, discusses results from the phase 3 FrontMIND trial which demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved progression-free survival, event-free survival, and molecular remission rates compared...
Georg Lenz, MD, discusses results from the phase 3 FrontMIND trial which demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved progression-free survival, event-free survival, and molecular remission rates compared...
Georg Lenz, MD, discusses...
06/18/2026
Oncology
News
Anti T-Lymphocyte Globulin Remains Standard GVHD Prophylaxis Following Unrelated Donor Transplantation
06/16/2026
Emily Estrada
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
Gilteritinib Fails to Improve OS in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3...
06/16/2026
Oncology
News
Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Emerges as Potential New Standard in Relapsed or Refractory Chronic Lymphocytic Leukemia
06/16/2026
Stephanie Holland
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN...
06/16/2026
Oncology
News
Switchable Allogeneic CAR T-Cell Therapy Shows Early Promise in Relapsed or Refractory Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a...
06/16/2026
Oncology
Enrique Ocio, MD, PhD
Videos
DREAMM-9 Final Analysis Shows Strong Efficacy With Belantamab Mafodotin Plus VRd in Newly Diagnosed Multiple Myeloma
06/16/2026
Enrique Ocio, MD, PhD
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses...
06/16/2026
Oncology
News
CD5 Inhibition Enhances Activity of T-Cell Engagers Across Tumor Types
06/16/2026
Stephanie Holland
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology
News
Blinatumomab Improves Survival and Reduces Toxicity in Pediatric Patients With High-Risk B-Acute Lymphoblastic Leukemia
06/15/2026
Stephanie Holland
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study...
06/15/2026
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses...
06/15/2026
Oncology
News
BAFF-R CAR T Therapy May Overcome Antigen Escape in Relapsed B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Bexobrutideg Continues to Demonstrate Clinical Promise Following BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
06/11/2026
Stephanie Holland
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase...
06/11/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
Dual-Target CAR T Therapy OL-101 Shows Deep Responses in Heavily Pretreated Patients With Relapsed or Relapsed Multiple Myeloma
06/11/2026
Stephanie Holland
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1...
06/11/2026
Oncology
Claire Harrison, MD
Videos
Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial
09/26/2025
Claire Harrison, MD
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares...
09/26/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Ziftomenib Plus Standard Induction Therapy Demonstrates Meaningful Clinical Activity for Patients With AML: KOMET-007
08/25/2025
Amer Zeidan, MBBS
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer...
08/25/2025
Oncology
Stefano Luminari, MD
Videos
Odronextamab Demonstrates Long-Term High Response Rates for Heavily Pretreated R/R Follicular Lymphoma: ELM-2
07/25/2025
Stefano Luminari, MD
At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of odronextamab therapy for patients with relapsed/refractory follicular lymphoma with a follow-up of more than 2 years.
At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of odronextamab therapy for patients with relapsed/refractory follicular lymphoma with a follow-up of more than 2 years.
At the EHA 2025 Congress,...
07/25/2025
Oncology
Raul Cordoba, MD
Conference Coverage
Epcoritamab Plus R-ICE Shows Deep Responses and Manageable Safety for Patients With DLBCL Eligible for ASCT: EPCORE NHL-2 Trial
07/10/2025
Raul Cordoba
At the EHA 2025 Congress, Raul Cordoba shared results from the EPCORE NHL-2 trial which evaluated the efficacy of epcoritamab combined with R-ICE therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
At the EHA 2025 Congress, Raul Cordoba shared results from the EPCORE NHL-2 trial which evaluated the efficacy of epcoritamab combined with R-ICE therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
At the EHA 2025 Congress, Raul...
07/10/2025
Oncology
Krish Patel, MD
Conference Coverage
Dual-Target CAR T-Cell Therapy Demonstrates Promising Response Rates for R/R LBCL
06/23/2025
Krish Patel, MD
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish...
06/23/2025
Oncology
Vincent Ribrag, MD
Videos
BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma
06/27/2023
Vincent Ribrag, MD
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
At the 2023 EHA Congress,...
06/27/2023
Oncology
News
PI3Kd Inhibitor YY-20394 Well Tolerated in Patients With R/R FL
10/19/2021
Phase 2 studying findings presented at the 2021 EHA Congress demonstrate the clinical efficacy of the PI3Kd inhibitor YY-20394 for the treatment of patients with R/R FL.
Phase 2 studying findings presented at the 2021 EHA Congress demonstrate the clinical efficacy of the PI3Kd inhibitor YY-20394 for the treatment of patients with R/R FL.
Phase 2 studying findings...
10/19/2021
Oncology
Dr Lydia Scarfò
Videos
MRD-Driven Therapy With Ibrutinib Plus Venetoclax for R/R CLL
08/12/2021
Lydia Scarfò, MD, discusses an MRD-driven treatment strategy with ibrutinib and venetoclax for R/R CLL. These data were presented at the 2021 EHA Virtual Congress.
Lydia Scarfò, MD, discusses an MRD-driven treatment strategy with ibrutinib and venetoclax for R/R CLL. These data were presented at the 2021 EHA Virtual Congress.
Lydia Scarfò, MD, discusses an...
08/12/2021
Oncology
Dr
Videos
Jeff Kutok, MD, PhD, on Targeting SETD2 in the Treatment of MM
06/28/2021
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical...
06/28/2021
Oncology
Videos
Sagar Lonial, MD, Discusses the TOURMALINE-MM4 Study
08/01/2020
Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.
Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.
Dr Lonial discusses a study on...
08/01/2020
Oncology
News
BTK Inhibitor Therapy Effective for Patients With High-Risk, Progressive CLL
07/17/2020
BTK inhibitor therapy is an effective option for patients with CLL resistant to venetoclax, according to data presented at the virtual 2020 EHA Annual Congress.
BTK inhibitor therapy is an effective option for patients with CLL resistant to venetoclax, according to data presented at the virtual 2020 EHA Annual Congress.
BTK inhibitor therapy is an...
07/17/2020
Oncology
Videos
Venetoclax Added to Azacitidine Improves Responses, OS in Older Patients With AML
07/15/2020
Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.
Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.
Courtney DiNardo, MD, discusses...
07/15/2020
Oncology
Videos
Addition of Parsaclisib to Ruxolitinib Therapy Shows Promise for Patients With Myelofibrosis
07/02/2020
Abdulraheem Yacoub, MD, discusses the results from a phase 2 study, which evaluated optimal dosing and efficacy of the addition of parsaclisib in patients with myelofibrosis with suboptimal response on ruxolitinib.
Abdulraheem Yacoub, MD, discusses the results from a phase 2 study, which evaluated optimal dosing and efficacy of the addition of parsaclisib in patients with myelofibrosis with suboptimal response on ruxolitinib.
Abdulraheem Yacoub, MD,...
07/02/2020
Oncology
Videos
Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL
06/29/2020
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Arnon P. Kater, MD, PhD,...
06/29/2020
Oncology
Videos
Roberto Mina, MD, Discusses Preliminary Results from the UNITO-EMN10 Study
06/26/2020
Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.
Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.
Roberto Mina, MD, discusses...
06/26/2020
Oncology
Conference Insider
Asciminib Well-Tolerated, Active in Heavily Pretreated Ph+ CML
06/23/2020
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.
Asciminib is well-tolerated and...
06/23/2020
Oncology
Videos
Ibrutinib Plus Venetoclax Yields High Rates of Undetectable MRD in CLL
06/22/2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Constantine Tam, MBBS (Hons),...
06/22/2020
Oncology
Conference Insider
Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM
06/22/2020
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
Ixazomib in combination with...
06/22/2020
Oncology
Conference Insider
Dasatinib Added to Induction Therapy Improves Outcomes in Ph+ ALL
06/19/2020
Dasatinib added to 2-step induction therapy improves pre-transplant treatment for patients with Philadelphia chromosome-positive ALL.
Dasatinib added to 2-step induction therapy improves pre-transplant treatment for patients with Philadelphia chromosome-positive ALL.
Dasatinib added to 2-step...
06/19/2020
Oncology
Videos
Triplet Combination Appears Well-Tolerated, Safe for DLBCL
06/18/2020
Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
Charles Herbaux, MD, MSc,...
06/18/2020
Oncology
Videos
Subcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL Amyloidosis
06/18/2020
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with AL amyloidosis.
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with AL amyloidosis.
Raymond Comenzo, MD, discusses...
06/18/2020
Oncology
Conference Insider
PET-CT Status After First Line Immunochemotherapy Prognostic for Survival in FL
06/17/2020
Achieving a PET-CT complete metabolic response after first line immunochemotherapy is strongly associated with improved survival outcomes in FL.
Achieving a PET-CT complete metabolic response after first line immunochemotherapy is strongly associated with improved survival outcomes in FL.
Achieving a PET-CT complete...
06/17/2020
Oncology
Videos
Glofitamab Demonstrates Strong Efficacy, Manageable Safety in Relapsed/Refractory NHL
06/17/2020
Michael Dickinson, MBBS (Hons), D.Med Sci, FRACP, FRCPA, discusses the results of a phase 1 dose escalation study of glofitamab in relapsed/refractory NHL.
Michael Dickinson, MBBS (Hons), D.Med Sci, FRACP, FRCPA, discusses the results of a phase 1 dose escalation study of glofitamab in relapsed/refractory NHL.
Michael Dickinson, MBBS (Hons),...
06/17/2020
Oncology
Videos
Acalabrutinib Demonstrates Favorable Safety and Efficacy in Relapsed/Refractory CLL
06/17/2020
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
Paolo Ghia, MD, PhD, discusses...
06/17/2020
Oncology

The EHA Annual Congress is a flagship meeting held in a major European city every June—a significant meeting place for hematologists from every area of specialization. The annual congresses encompass the entire spectrum of hematological studies, where over 11,000 participants can learn about the latest findings and innovations in hematologic diseases.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use